Servier

Artificial Intelligence for New Drug Design

Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.

Servier Buys Denmark’s Symphogen

Servier Gets Blood Cancer Drug from CTI BioPharma

Shire sells Oncology Portfolio to Servier

Shire Sells Oncology Unit to Servier for $2.4 Billion

GSK Fined for Blocking Copies of Seroxat

Lundbeck, Merck KGaA and Others Fined for Blocking Rival Drugs

EU to Fine Lundbeck, Others for Blocking Generic Drugs

EU to Charge Servier, Lundbeck over Generics

Global Pharma to Pump Cash Into Russia

EU To Seek Details Of Deals Delaying Generic Drugs